Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
In accordance with the French law of September 5, 2018 on “The freedom to choose a professional future”, and in accordance with the French decree of January 8, 2019 which stipulates that all companies of more than 50 employees must set up a Professional Equality Index for women and men, Oncodesign publishes its own Professional Equality Index. This obligation is in line with Oncodesign’s commitment to professional equality in line with its dynamic of growth and development.
This index, which is the same in all companies, makes it possible to assess professional equality between women and men within companies via an overall score out of 100 points calculated using the 4 following indicators:
Gender pay gap (40 points)
Difference in the proportion of women and men getting pay raises (35 points)
Percentage of female employees getting a pay raise on their return from maternity leave (15 points)
Number of employees of the underrepresented gender among the 10 highest pay grades (10 points)
Measured for the first time in 2019, our Professional Equality Index is 76 points.
We are proud to announce that we have made progress in 2020:
"2020 PROFESSIONAL EQUALITY INDEX: 84 points"
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260